Midori Ishii
YOU?
Author Swipe
View article: Early Epcoritamab Administration Revives CAR‐T Cells in Relapsed/Refractory B‐Cell Lymphomas
Early Epcoritamab Administration Revives CAR‐T Cells in Relapsed/Refractory B‐Cell Lymphomas Open
Background Bispecific antibodies are effective for relapsed/refractory B‐cell lymphoma patients even after CAR‐T therapy. Methods Peripheral blood CAR‐T kinetics and functional analysis in vivo were carried out pre‐ and post‐epcoritamab in…
View article: Immune recovery in tumor microenvironment of<i>TP53</i>-mutated AML following venetoclax combination therapy
Immune recovery in tumor microenvironment of<i>TP53</i>-mutated AML following venetoclax combination therapy Open
Highlights Single-cell RNA sequencing of bone marrow from TP53-mutated AML patients showed a decrease in cells expressing anti-apoptotic genes like BCL2 and MCL1 after venetoclax and azacitidine treatment. Immune cells increased both in nu…
View article: Generation of iPSC-derived CD4<sup>+</sup>Th1 cells enhancing chimeric antigen receptor-T cell cytotoxicity
Generation of iPSC-derived CD4<sup>+</sup>Th1 cells enhancing chimeric antigen receptor-T cell cytotoxicity Open
Summary CD4 + T cells are anticipated to enhance the overall immune response, including the anti-tumor activity of chimeric antigen receptor (CAR)-T cell therapy. In the past, we established a culture system to generate CD8 + T cells from …
View article: Eleven cases of laryngeal edema after tisagenlecleucel infusion: a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas
Eleven cases of laryngeal edema after tisagenlecleucel infusion: a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas Open
Not available.
View article: Data from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Data from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Small cell lung cancer (SCLC) is exceptionally aggressive, with limited treatment options. Disialoganglioside (GD2) is highly expressed on SCLC and is considered a good target for chimeric antigen receptor (CAR) T cells (CART). Although GD…
View article: Data from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Data from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Small cell lung cancer (SCLC) is exceptionally aggressive, with limited treatment options. Disialoganglioside (GD2) is highly expressed on SCLC and is considered a good target for chimeric antigen receptor (CAR) T cells (CART). Although GD…
View article: FIGURE 4 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
FIGURE 4 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
scRNA-seq analysis of GD2-2840-CARTs and GD2-CARrejT. A and B, UMAP projection of scRNA-seq data of GD2-2840z-CARTs and GD2-CARrejTs. Cluster gene characteristics determine cluster functional description. Cluster 1: CD4+…
View article: Supplementary Figure 2 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Supplementary Figure 2 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Supplementary Figure S2 showcases the functional and phenotypic analysis of GD2-CARTs and GD2-CARrejTs, including cytokine production (IL-4, IL-6, IL-10, and IL-17A) through cytometric bead assays, flow cytometry gating strategies, memory …
View article: Supplementary Figure 3 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Supplementary Figure 3 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Supplementary Figure S3 demonstrates the expression profiles of signature genes (including lineage, co-stimulation, co-inhibition, cytotoxic molecules, and transcription factors) in GD2-2840z-CARTs, GD2-CARrejTs, and control T cells throug…
View article: Supplementary Figure 4 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Supplementary Figure 4 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Supplementary Figure S4 presents flow cytometric analysis of PD-1, TIGIT, and CD226 expression on GD2-2840z-CARTs and GD2-CARrejTs after coculture with SCLC-J1 cells, based on three independent experiments. It also features real-time cell …
View article: Supplementary Figure 2 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Supplementary Figure 2 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Supplementary Figure S2 showcases the functional and phenotypic analysis of GD2-CARTs and GD2-CARrejTs, including cytokine production (IL-4, IL-6, IL-10, and IL-17A) through cytometric bead assays, flow cytometry gating strategies, memory …
View article: FIGURE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
FIGURE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Generation of GD2-CARTs. A, GD2 expression by NSCLC cell line (negative control) and by four SCLC cell lines (red), with isotype control (blue). The plots represent three independent experiments. B, Schema, lentiviral GD2-CAR…
View article: Supplementary Figure 4 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Supplementary Figure 4 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Supplementary Figure S4 presents flow cytometric analysis of PD-1, TIGIT, and CD226 expression on GD2-2840z-CARTs and GD2-CARrejTs after coculture with SCLC-J1 cells, based on three independent experiments. It also features real-time cell …
View article: FIGURE 5 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
FIGURE 5 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Blockade of TIGIT and PD-1 augments cytotoxicity of GD2 2840z-CARTs. A, Schema of immune-regulatory mechanism of T cells against SCLC. B, Flow cytometric analysis of TIGIT and CD226 expression on GD2-2840z-CARTs and GD2-CARre…
View article: FIGURE 3 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
FIGURE 3 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Robust tumor suppressive effect of GD2-CARrejTs in vivo.A, Graphical abstract of in vivo experiment. H446 cells labeled with FFluc/GFP were intravenously injected into NOG mice (1 × 106 cells/mouse) 4 days b…
View article: FIGURE 3 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
FIGURE 3 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Robust tumor suppressive effect of GD2-CARrejTs in vivo.A, Graphical abstract of in vivo experiment. H446 cells labeled with FFluc/GFP were intravenously injected into NOG mice (1 × 106 cells/mouse) 4 days b…
View article: FIGURE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
FIGURE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Generation of GD2-CARTs. A, GD2 expression by NSCLC cell line (negative control) and by four SCLC cell lines (red), with isotype control (blue). The plots represent three independent experiments. B, Schema, lentiviral GD2-CAR…
View article: TABLE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
TABLE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Primer and probe information
View article: FIGURE 5 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
FIGURE 5 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Blockade of TIGIT and PD-1 augments cytotoxicity of GD2 2840z-CARTs. A, Schema of immune-regulatory mechanism of T cells against SCLC. B, Flow cytometric analysis of TIGIT and CD226 expression on GD2-2840z-CARTs and GD2-CARre…
View article: Supplementary Figure 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Supplementary Figure 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Supplementary Figure S1 illustrates the cytotoxic effects of GD2-CARTs (GD2-2840z-CARTs, GD2-28z-CARTs, and GD2-BBz-CARTs) and control T cells on GD2+ tumor cells through in vitro 51Cr release assays.
View article: Supplementary Figure 3 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Supplementary Figure 3 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Supplementary Figure S3 demonstrates the expression profiles of signature genes (including lineage, co-stimulation, co-inhibition, cytotoxic molecules, and transcription factors) in GD2-2840z-CARTs, GD2-CARrejTs, and control T cells throug…
View article: FIGURE 2 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
FIGURE 2 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Generation of GD2-CARrejTs. A, Schema, generation of GD2-CARrejTs. T-iPSCs established from LMP2-specific CTL clones were transduced with lentiviral GD2-CAR and GD2-CAR-iPSCs were differentiated into GD2-CARrejTs. B, Flow cyt…
View article: TABLE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
TABLE 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Primer and probe information
View article: FIGURE 4 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
FIGURE 4 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
scRNA-seq analysis of GD2-2840-CARTs and GD2-CARrejT. A and B, UMAP projection of scRNA-seq data of GD2-2840z-CARTs and GD2-CARrejTs. Cluster gene characteristics determine cluster functional description. Cluster 1: CD4+…
View article: FIGURE 2 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
FIGURE 2 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Generation of GD2-CARrejTs. A, Schema, generation of GD2-CARrejTs. T-iPSCs established from LMP2-specific CTL clones were transduced with lentiviral GD2-CAR and GD2-CAR-iPSCs were differentiated into GD2-CARrejTs. B, Flow cyt…
View article: Supplementary Figure 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Supplementary Figure 1 from Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Supplementary Figure S1 illustrates the cytotoxic effects of GD2-CARTs (GD2-2840z-CARTs, GD2-28z-CARTs, and GD2-BBz-CARTs) and control T cells on GD2+ tumor cells through in vitro 51Cr release assays.
View article: Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer
Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer Open
Small cell lung cancer (SCLC) is exceptionally aggressive, with limited treatment options. Disialoganglioside (GD2) is highly expressed on SCLC and is considered a good target for chimeric antigen receptor (CAR) T cells (CART). Although GD…
View article: Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline DDX41-mutated acute myeloid leukemia
Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline DDX41-mutated acute myeloid leukemia Open
View article: iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer
iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer Open
View article: Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma
Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma Open